Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0034065 (pulmonary embolism)
 14,979 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Drug-induced pulmonary toxicities of anticancer agents have been well described, but the pathophysiology of agents typically used in advanced disease has not been well studied. Symptoms of pulmonary drug toxicity in advanced lung cancer patients may frequently be attributed to disease progression, pulmonary embolism, or infection. In patients with pre-existing interstitial pulmonary fibrosis even less is known. This report describes an unfortunate patient with pre-existing pulmonary fibrosis and progressive extensive stage small cell lung cancer. After receiving a single intravenous dose of topotecan, the patient developed sub-acute respiratory failure, and died 15 days later with pathology findings of organizing, reparative phase, diffuse alveolar damage. To our knowledge this is the first pathology confirmation of diffuse alveolar damage in a patient developing dyspnea following topotecan therapy. The frequency with which camptothecin-related dyspnea is associated with diffuse alveolar damage might be underestimated and is of special concern in patients with limited pulmonary reserve.
 ...
PMID:Diffuse alveolar damage after a single dose of topotecan in a patient with pulmonary fibrosis and small cell lung cancer. 1694

Thrombosis involving the subclavian vein and superior vena cava is relatively common, especially in cancer patients. Edema of the arms and head is a well-known clinical consequence of this thrombosis. The intrinsic risk of pulmonary embolism has not been reported previously. Herein, we describe the case of a 63-year-old male patient with extensive stage small cell lung cancer who developed superior vena cava syndrome. Pulmonary thromboembolism was complicated after receiving systemic chemotherapy and localized radiotherapy. <Learning objective: Superior vena cava (SVC) syndrome may pose a significant risk factor of pulmonary thromboembolism. Although SVC syndrome and pulmonary thromboembolism may have similar comorbidities, pulmonary thromboembolism might occur after treatment of SVC syndrome. Possible mechanisms may be related to tumor debris and hypercoagulable central vein thrombosis. Physicians must be vigilant with patients whom have dyspnea after treatment of SVC syndrome. Computed tomography angiography may help make an early diagnosis if clinical suspicion is made.>.
 ...
PMID:Superior vena cava syndrome complicated with acute pulmonary thromboembolism in a patient with lung cancer. 3027 43